RCT | Fruquintinib extends median survival to 7.4 months vs. 4.8 months with placebo in refractory metastatic colorectal cancer

Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study – The Lancet (link to abstract – $ for full-text)

Commentary on Twitter questioning the control group (thread – click for more)

Disgusting, unethical PLACEBO control trial in colon cancer just so Fruquitinib can win

I will show you that placebo should not have been the control arm, & the IRBs & FDA failed ?

First, this trial tests a new drug vs. placebo (sugar pill) in patients dying of colon cancer pic.twitter.com/fa915vgUbp

— Vinay Prasad MD MPH (@VPrasadMDMPH) June 17, 2023